Muscle-Invasive Bladder Carcinoma Clinical Trial
Official title:
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.
Aura is conducting a Phase 1, 'window of opportunity', open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intratumoral injection with or without intramural injection and with or without laser application in subjects with bladder cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05097404 -
Clinical Utility of VI-RADS in Diagnosis of MIBC
|
||
Not yet recruiting |
NCT04966130 -
Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
|
||
Active, not recruiting |
NCT04610671 -
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
|
Phase 1 | |
Recruiting |
NCT06341400 -
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06190197 -
Prophylactic Antibiotics in Cystectomy With Diversion
|
Early Phase 1 | |
Recruiting |
NCT05203913 -
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05790850 -
Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
|
N/A | |
Recruiting |
NCT05833867 -
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05295992 -
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
|
N/A | |
Recruiting |
NCT06215976 -
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
|
Phase 4 | |
Recruiting |
NCT05028660 -
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
|
||
Not yet recruiting |
NCT06417190 -
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
|
Phase 2 | |
Not yet recruiting |
NCT04909775 -
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT04876313 -
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
|
Phase 2 | |
Not yet recruiting |
NCT04686149 -
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
|
||
Active, not recruiting |
NCT05630131 -
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
|
||
Recruiting |
NCT06170177 -
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
|
||
Terminated |
NCT05221827 -
Clinical Performance Evaluation of the C2i-Test
|
||
Recruiting |
NCT06257017 -
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
|
Phase 2 | |
Recruiting |
NCT05767528 -
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
|